Clinical Trial Update: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of the DLL3-targeting radiopharmaceutical [212Pb]Pb-DOTAM-MAM279 (MP0712) in small cell lung cancer and other DLL3-expressing solid t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Neuroendocrine Carcinoma
• Gastroenteropancreatic Neuroendocrine Carcinoma
• Large Cell Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma of the Bladder
• Small Cell Lung Cancer

Drugs mentioned

• MP0712 (MP0712 DLL3-targeting radiopharmaceutical (Lead-212 DOTAM-MAM279))
• [212Pb]Pb-DOTAM-MAM279 (Lead-212 DOTAM-MAM279 radiopharmaceutical targeting DLL3)

Snippet

Sponsor: Molecular Partners AG | Conditions: Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) | Phase 1, Phase 2 | Status: RECRUITING